Genetic engineering is the science of reading or changing genetic material to understand and treat disease. This theme includes companies developing gene editing, gene therapy, RNA-based medicines and engineered cell therapies, plus the life-science toolmakers that supply DNA sequencing, synthetic DNA, lab instruments and research services, and several genomics ETFs. Many of these medicines are still in clinical trials, so outcomes can be all-or-nothing.
Note: This Public Theme is based on data from one or more third-party data providers. This Theme is provided for informational purposes only by Public Holdings, Inc., and is not investment advice or an investment recommendation. You should not buy or sell anything included in this Public Theme without first determining it is appropriate for your portfolio or investment strategy. Investors should consider the investment objectives and unique risk profile of an Exchange Traded Product (“ETP”) and read the ETP’s prospectus carefully before investing.
